Kinase Inhibitors in Cancer and Central Nervous System

Guest Editor:

**Prof. Dr. Thierry Besson**
Normandie Univ, Univ Rouen; INSA Rouen, CNRS, Laboratoire COBRA UMR6014Bâtiment IRCOF, 1 rue Tesnière, F-76821 Mont Saint-Aignan Cedex, France
thierry.besson@univ-rouen.fr

Deadline for manuscript submissions:
28 March 2019

**Message from the Guest Editor**

Protein kinases catalyse protein phosphorylation—a key cellular regulatory mechanism which is frequently dysregulated in human diseases. Kinases have consequently been linked to the progress of a variety of diseases, including cancer and neurodegenerative disorders. Therefore, the search for therapeutic inhibitors of specific kinases has been developed in the last three decades as a major approach to discovering new therapeutic drugs. Initially focused on the discovery, optimization, and characterization of tyrosine kinase inhibitors and on cancer indications, the field is now rapidly expanding towards serine/threonine kinases and essentially all other therapeutic indications as neurodegenerative diseases (Alzheimer’s disease, Down syndrome).

In this Special Issue, our goal is to highlight papers describing an intended inhibition of specific kinases, although they are not always the initial and main target of the compounds tested. In silico molecular design connected with the development of chemical syntheses and pertinent comments on the forthcoming applications of these inhibitors will be particularly appreciated.